Surovi Hazarika1, Brian H Annex2. 1. Division of Cardiovascular Medicine and Robert Bernie Cardiovascular Research Center, University of Virginia, Charlottesville, VA. 2. Division of Cardiovascular Medicine and Robert Bernie Cardiovascular Research Center, University of Virginia, Charlottesville, VA. bha4n@hscmail.mcc.virginia.edu.
Abstract
BACKGROUND: Peripheral artery disease (PAD) is highly prevalent and there is considerable diversity in the initial clinical manifestation and disease progression among individuals. Currently, there is no ideal biomarker to screen for PAD, to risk stratify patients with PAD, or to monitor therapeutic response to revascularization procedures. Advances in human genetics have markedly enhanced the ability to develop novel diagnostic and therapeutic approaches across a host of human diseases, but such developments in the field of PAD are lagging. CONTENT: In this article, we will discuss the epidemiology, traditional risk factors for, and clinical presentations of PAD. We will discuss the possible role of genetic factors and gene-environment interactions in the development and/or progression of PAD. We will further explore future avenues through which genetic advances can be used to better our understanding of the pathophysiology of PAD and potentially find newer therapeutic targets. We will discuss the potential role of biomarkers in identifying patients at risk for PAD and for risk stratifying patients with PAD, and novel approaches to identification of reliable biomarkers in PAD. SUMMARY: The exponential growth of genetic tools and newer technologies provides opportunities to investigate and identify newer pathways in the development and progression of PAD, and thereby in the identification of newer biomarkers and therapies.
BACKGROUND:Peripheral artery disease (PAD) is highly prevalent and there is considerable diversity in the initial clinical manifestation and disease progression among individuals. Currently, there is no ideal biomarker to screen for PAD, to risk stratify patients with PAD, or to monitor therapeutic response to revascularization procedures. Advances in human genetics have markedly enhanced the ability to develop novel diagnostic and therapeutic approaches across a host of human diseases, but such developments in the field of PAD are lagging. CONTENT: In this article, we will discuss the epidemiology, traditional risk factors for, and clinical presentations of PAD. We will discuss the possible role of genetic factors and gene-environment interactions in the development and/or progression of PAD. We will further explore future avenues through which genetic advances can be used to better our understanding of the pathophysiology of PAD and potentially find newer therapeutic targets. We will discuss the potential role of biomarkers in identifying patients at risk for PAD and for risk stratifying patients with PAD, and novel approaches to identification of reliable biomarkers in PAD. SUMMARY: The exponential growth of genetic tools and newer technologies provides opportunities to investigate and identify newer pathways in the development and progression of PAD, and thereby in the identification of newer biomarkers and therapies.
Authors: Salvatore Santo Signorelli; Grazia Malaponte; Massimo Libra; Luigi Di Pino; Gabriella Celotta; Valentina Bevelacqua; Marcello Petrina; Giuseppina S Nicotra; Manuela Indelicato; Patrick M Navolanic; Giuseppe Pennisi; Maria Clorinda Mazzarino Journal: Vasc Med Date: 2005-02 Impact factor: 3.239
Authors: M M McDermott; P Greenland; K Liu; J M Guralnik; M H Criqui; N C Dolan; C Chan; L Celic; W H Pearce; J R Schneider; L Sharma; E Clark; D Gibson; G J Martin Journal: JAMA Date: 2001-10-03 Impact factor: 56.272
Authors: E Ciccarone; A Di Castelnuovo; D Assanelli; S Archetti; G Ruggeri; N Salcuni; M B Donati; F Capani; L Iacoviello Journal: J Thromb Haemost Date: 2003-12 Impact factor: 5.824
Authors: T Mueller; B Dieplinger; A Gegenhuber; D Haidinger; N Schmid; N Roth; F Ebner; M Landl; W Poelz; M Haltmayer Journal: J Vasc Surg Date: 2004-10 Impact factor: 4.268
Authors: Himabindu Vidula; Lu Tian; Kiang Liu; Michael H Criqui; Luigi Ferrucci; William H Pearce; Philip Greenland; David Green; Jin Tan; Daniel B Garside; Jack Guralnik; Paul M Ridker; Nader Rifai; Mary M McDermott Journal: Ann Intern Med Date: 2008-01-15 Impact factor: 25.391
Authors: Steven Menez; Ning Ding; Morgan E Grams; Pamela L Lutsey; Gerardo Heiss; Aaron R Folsom; Elizabeth Selvin; Josef Coresh; Bernard G Jaar; Kunihiro Matsushita Journal: Nephrol Dial Transplant Date: 2020-11-01 Impact factor: 5.992
Authors: Emmi Tikkanen; Vilma Jägerroos; Michael V Holmes; Naveed Sattar; Mika Ala-Korpela; Pekka Jousilahti; Annamari Lundqvist; Markus Perola; Veikko Salomaa; Peter Würtz Journal: J Am Heart Assoc Date: 2021-11-30 Impact factor: 6.106
Authors: Lingyao Zeng; Sylvain Moser; Nazanin Mirza-Schreiber; Claudia Lamina; Stefan Coassin; Christopher P Nelson; Tarmo Annilo; Oscar Franzén; Marcus E Kleber; Salome Mack; Till F M Andlauer; Beibei Jiang; Barbara Stiller; Ling Li; Christina Willenborg; Matthias Munz; Thorsten Kessler; Adnan Kastrati; Karl-Ludwig Laugwitz; Jeanette Erdmann; Susanne Moebus; Markus M Nöthen; Annette Peters; Konstantin Strauch; Martina Müller-Nurasyid; Christian Gieger; Thomas Meitinger; Elisabeth Steinhagen-Thiessen; Winfried März; Andres Metspalu; Johan L M Björkegren; Nilesh J Samani; Florian Kronenberg; Bertram Müller-Myhsok; Heribert Schunkert Journal: Cardiovasc Res Date: 2022-03-16 Impact factor: 10.787